Article Information
History
- August 5, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Aganze Gloire-Aimé Mushebenge1,2,3,*,
- Samuel Chima Ugbaja2,
- Nonkululeko Avril Mbatha3,
- Manimani Ghislain Riziki4,
- Tambwe Willy Muzumbukilwa1,
- Mukanda Gedeon kadima1 and
- Hezekiel M. Kumalo2,*
- 1Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Westville-Durban, South Africa
- 2Drug Research and Innovation Unit, Discipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban 4000, South Africa
- 3Faculty of Pharmaceutical Sciences, University of Lubumbashi, Democratic Republic of Congo
- 4KwaZulu-Natal Research Innovation and Sequencing Platform, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban 4000, South Africa
- 5Department of Internal Medicine, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban 4000, South Africa
- ↵*Corresponding author: Aganze Gloire-Aimé Mushebenge, Email: aganzedar{at}Gmail.com, alternative e-mail: Kumaloh{at}ukzn.ac.za
Posted August 05, 2023.
Systematic Review and Meta-Analysis Protocol of the Efficacy and Safety of COVID-19 Drug Candidates Targeting Host Enzymes Involved in Immune Response
